PDEX carries a meaningful short position into its Q3 2026 results — and the borrowing market suggests bears have conviction rather than urgency.
Short interest runs at nearly 7% of the free float, a level that has edged higher by roughly 5% over the past month. The lending environment is not yet stressed: borrow availability points to roughly half the lending pool still unused, and the cost to borrow is just 0.76% annualised — low enough that holding a short position remains cheap. What gives the short setup real texture is the ORTEX short score: at 74.4, it ranks PDEX in the 97th percentile of the universe on short-score intensity. That score has been drifting lower from 76.3 two weeks ago, suggesting some incremental short-covering — but the position remains large for a company of this size.
The bull case centres on genuine operational momentum. Last quarter, revenue came in at $18.5m, up 24% year on year, with an EBITDA margin near 18% and a net income margin above 25% boosted by a favourable tax item. Operating cash flow was positive. Days to cover runs nearly 15 — meaning bears need two full trading weeks of average volume to exit. Ascendiant Capital, the sole covering analyst, has raised its target four times since late 2024, most recently to $56 in May 2025, maintaining a Buy rating. The stock at $50.14 implies about 12% upside to that target — consistent with a modest valuation stretch at a trailing P/E around 21x and EV/EBITDA near 14x. Bear concerns, flagged when the estimate revision cycle was active, include slowing revenue growth, margin pressure from product mix, and the inherent concentration risk of a company this small in a competitive medical device niche.
The ownership structure adds an interesting wrinkle. AO Partners holds roughly 29% of shares outstanding — a dominant anchor position. The most recent insider data (from November 2025) shows a director adding just over 3,000 shares at around $32-33, while token sales from the COO, CFO and a director represent routine compensation disposals rather than a bearish signal. The stock has since rallied roughly 53% from those insider purchase levels, which may be part of what attracts the elevated short interest: bears can point to a stock that has moved sharply relative to its fundamental anchor.
Peers have been weak in the past week — BFLY fell 11%, ARAY dropped nearly 10%, and QDEL slid 3.5% — while PDEX gave back just 1.6%. That relative resilience, combined with a 6% rise over the past month, sets up a test of whether the recent outperformance reflects genuine business execution or temporary positioning. With the EPS surprise factor ranked at the 76th percentile, the print will ultimately settle whether the company's history of beating expectations can withstand scrutiny at a valuation level the short side clearly finds stretched.
See the live data behind this article on ORTEX.
Open PDEX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
